PTK7 and neoplasm: The authors of the latter study also developed a PTK7-targeted antibody-drug conjugate and showed that its application reduces tumor initiating cells and induces sustained tumor regressions, paving the way for a PTK7-directed anti-tumor therapy (Damelin et al., 2017).